Spheramine(r) phase IIB study did not meet endpoints
 

Titan Pharmaceuticals Announces Spheramine(R) Initial Phase IIb Results
07.02.08, 7:01 AM ET

Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced initial analyses show that Spheramine(R) did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up. The Phase IIb trial was designed to explore the safety, tolerability and efficacy of Spheramine, the company's novel cell-based therapy for the potential treatment of moderate to advanced Parkinson's disease.

read the entire article
http://www.forbes.com/businesswire/f...2005205r1.html